Gilead Sciences GILD Other HIV — Total revenues

Other product segments

Similar metrics at other companies

INCYProduct And Service Other — Revenue

$58K+105%

BIIBOther corporate revenues — Product revenues

$114.2M-20.6%

INCYNet sales — Total revenues

$1.1B+19.8%

INCYOther product royalty revenues — Total revenues

$3.25M+156%

ILMNOther Products — Revenue

$6M+14.3%

GHLicensing and other — Total Revenue

$2.14M+15.3%

Questions, answered.

What is Gilead Sciences's other HIV — total revenues?

Gilead Sciences (GILD) reported other HIV — total revenues of $73M in Q1 2026.

How has Gilead Sciences's other HIV — total revenues changed year-over-year?

Gilead Sciences's other HIV — total revenues decreased by 19.8% year-over-year, from $91M to $73M.

What is the long-term trend for Gilead Sciences's other HIV — total revenues?

Over 3 years (2022 to 2025), Gilead Sciences's other HIV — total revenues has grown at a -1.9% compound annual growth rate (CAGR), from $530M to $500M.

What does other HIV — total revenues mean?

The total sales revenue generated from secondary or niche HIV treatment products.

How do you interpret other HIV — total revenues?

An increase suggests successful lifecycle management or sustained demand for secondary therapies, while a decrease may indicate product obsolescence or market share erosion by newer, more effective treatments.

How does other HIV — total revenues compare across companies?

Peers in the pharmaceutical industry typically report similar secondary segment revenues to track the tail-end performance of older drug portfolios versus high-growth flagship products.